| Literature DB >> 27469115 |
Danielle F Eytan1,2,3, Grace E Snow1,2, Sophie Carlson1, Adeeb Derakhshan1,2, Anthony Saleh1, Stephen Schiltz1, Hui Cheng1, Suresh Mohan1,2, Shaleeka Cornelius1, Jamie Coupar1, Anastasia L Sowers4, Lidia Hernandez5, James B Mitchell4, Christina M Annunziata5, Zhong Chen1, Carter Van Waes1.
Abstract
Comparison of tumors from The Cancer Genome Atlas (TCGA) reveals that head and neck squamous cell carcinomas (HNSCC) harbor the most frequent genomic amplifications of Fas-associated death domain (FADD), with or without Baculovirus inhibitor of apoptosis repeat containing BIRC2 (cIAP1), affecting about 30% of patients in association with worse prognosis. Here, we identified HNSCC cell lines harboring FADD/BIRC2 amplifications and overexpression by exome sequencing, RT-PCR, and Western blotting. In vitro, FADD or BIRC2 siRNA knockdown inhibited HNSCC displaying amplification and increased expression of these genes, supporting their functional importance in promoting proliferation. Birinapant, a novel SMAC mimetic, sensitized multiple HNSCC lines to cell death by agonists TNFα or TRAIL and inhibited cIAP1>XIAP>IAP2. Combination of birinapant and TNFα induced sub-G0 DNA fragmentation in sensitive lines and birinapant alone also induced significant G2-M cell-cycle arrest and cell death in UM-SCC-46 cells. Gene transfer and expression of FADD sensitized resistant UM-SCC-38 cells lacking FADD amplification to birinapant and TNFα, supporting a role for FADD in sensitization to IAP inhibitor and death ligands. HNSCC varied in mechanisms of cell death, as indicated by reversal by inhibitors or protein markers of caspase-dependent apoptosis and/or RIPK1/MLKL-mediated necroptosis. In vivo, birinapant inhibited tumor growth and enhanced radiation-induced TNFα, tumor responses, and host survival in UM-SCC-46 and -11B xenograft models displaying amplification and overexpression of FADD+/- BIRC2 These findings suggest that combination of SMAC mimetics such as birinapant plus radiation may be particularly active in HNSCC, which harbor frequent FADD/BIRC2 genomic alterations. Cancer Res; 76(18); 5442-54. ©2016 AACR. ©2016 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27469115 PMCID: PMC5026594 DOI: 10.1158/0008-5472.CAN-15-3317
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701